

**EITA INDIA LIMITED**  
 [FORMERLY: E.I.T.A India Limited]  
 CIN: L51109WB1983PLC035969  
 Regd. Office: 20-B, Abdul Hamid Street,  
 4th Floor, Kolkata-700 069,  
 Phone: 033-22483203  
 E-mail: eita.cal@eita.com,  
 Website: www.eita.com

## NOTICE

Notice is hereby given that pursuant to Regulation 29 read with Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 meeting of the Board of Directors of the Company will be held at its Registered office at 208 Abdul Hamid Street, 4th Floor, Kolkata-700069 on Tuesday 12th August, 2025 at 1.00 P.M., inter alia to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2025.

By Order of the Board  
 For EITA India Limited  
 Sd/-

Date: 04.08.2025 Arvind Kumar Lohia  
 Place: Kolkata Managing Director  
 The Notice is also available on the Company's website at [www.eita.com](http://www.eita.com) and on the Stock Exchange website at [www.csie.com](http://www.csie.com).



## QGO FINANCE LIMITED

CIN : L65910MH1993PLC30245

Regd Office: 3rd Floor, A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 400701  
 E: [Contactus@qgofinance.com](mailto:Contactus@qgofinance.com) / Website: [www.qgofinance.com](http://www.qgofinance.com) / Tel No.: +91-8657400776

### [Regulation 47 of the SEBI (LODR) Regulations, 2015]

BSE Code - 538646

#### Extract of Un-Audited Financial Results for the quarter ended June 30, 2025

The Un-Audited Financial Results of QGO Finance Limited ("the Company") along with the Limited Review Report received from the Statutory Auditors of the Company for the Quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by Board of Directors of the Company at their Meetings held on August 04, 2025, in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforementioned Financial Results along with the Limited Review Report of the Statutory Auditors thereon are available on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and on the Company's website at [https://qgofinance.com/](http://www.qgofinance.com). The same can also be accessed by scanning the QR Code provided below:



Date: 04/08/2025  
 Place: Navi Mumbai

By order of the Board  
 For QGO Finance Limited  
 sd/-  
 Rachana Singi  
 Managing Director

THIS IS A PUBLIC ANNOUNCEMENT FOR AN INFORMATION PURPOSE ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT.  
 THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.

THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

#### PUBLIC ANNOUNCEMENT



(Please scan this QR code  
 to view the Draft Red  
 Herring Prospectus)

## NEOCHEM

Enabling Growth

### NEOCHEM BIO SOLUTIONS LIMITED

(Formerly known as Neochem Bio Solutions Private Limited and Neochem Technologies Private Limited)

CORPORATE IDENTIFICATION NUMBER: U24304GJ2017PLC097754

Our Company was originally formed as a partnership firm under the Indian Partnership Act, 1932 ("Partnership Act") in the name and style of "M's Vinayak Dyes & Chemical Industries", pursuant to Deed of Partnership dated March 6, 1978. Vinayak Dyes & Chemical Industries was changed to "Neochem Technologies" with effect from January 6, 2006 and further the firm was converted from Partnership Firm to Private Limited company under Part I chapter XXI of the Companies Act, 2013 and received a Certificate of Incorporation from Registrar of Companies, Ahmedabad at Gujarat ("RoC") on June 6, 2017 as "Neochem Technologies Private Limited". Furthermore, the name of our Company was changed from Neochem Technologies Private Limited to Neochem Bio Solutions Private Limited and Certificate of Name change dated March 18, 2025 was received by the Company. Subsequently, our Company was converted into a public limited company pursuant to a special resolution passed by our shareholders resolution dated March 26, 2025, and the name of our Company was changed to "Neochem Bio Solutions Limited". A fresh certificate of Incorporation consequent upon conversion from a Private Limited company to Public Limited company dated April 15, 2025 was issued by the Registrar of Companies, Central Processing Centre. For details of the change in the registered office of our Company, see "History and Certain Corporate Matters" on page 200 of the Draft Red Herring Prospectus.

Registered Office: 303, W1, Opp. Vikramnagar Colony, Off. Iscon - Ambli Road, Ambli, Ahmedabad - 380058, Daskroi, Gujarat, India.

Website: [www.neochem.in](http://www.neochem.in); E-Mail: [compliance@neochem.in](mailto:compliance@neochem.in); Telephone No: +91-079-35217792

Company Secretary and Compliance Officer: Shraddha Sarthak Agarwal; Chief Financial Officer: Pradip Ramniklal Solanki

#### PROMOTERS OF OUR COMPANY: SWAPNIL RAMESHBHAI MAKATI AND HEMANGINI SWAPNIL DATHIA

#### THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 47,50,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH OF NEOCHEM BIO SOLUTIONS LIMITED (FORMERLY KNOWN AS NEOCHEM BIO SOLUTIONS PRIVATE LIMITED & NEOCHEM TECHNOLOGIES PRIVATE LIMITED), ("NEOCHEM" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹[●]/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGRGATING TO ₹[●] LAKHS ("THE ISSUE"), OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹[●]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹[●]/- PER EQUITY SHARE AGGRGATING TO ₹[●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹[●]/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹[●]/- PER EQUITY SHARE AGGRGATING TO ₹[●] LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [●] % AND [●] %, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER ADVERTISED IN ALL EDITION OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND ALL EDITION OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND GUJARATI EDITION OF [●] (A WIDELY CIRCULATED GUJARATI DAILY NEWSPAPER, GUJARATI BEING THE REGIONAL LANGUAGE OF GUJARAT, WHERE OUR REGISTERED OFFICE IS LOCATED). AT LEAST TWO WORKING DAYS PRIOR TO THE ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE") FOR THE PURPOSE OF UPLOADING ON THEIR WEBSITE. FOR FURTHER DETAILS, KINDLY REFER TO CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 305 OF THE DRAFT RED HERRING PROSPECTUS.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least 3 (three) additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 (ten) Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum of 1 (one) Working Day, subject to the Bid/Issue Period not exceeding 10 (ten) Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange, by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

#### THE FACE VALUE OF THE EQUITY SHARES IS ₹10/- EACH AND THE ISSUE PRICE IS [●] TIMES OF THE FACE VALUE

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than ₹10 lakhs; and (c) any unreserved portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non-Institutional Investors; and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, as applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 320 of the Draft Red Herring Prospectus.

This Public Announcement is made pursuant to Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2025 vide notification dated March 03, 2025.

The DRHP filed with the NSE EMERGE shall be made available for the public comments, if any, for the period of at least 21 days from the date of such filing and hosting the same on the website of the NSE at [www.nseindia.com](http://www.nseindia.com), website of the Issuer at [www.neochem.in](http://www.neochem.in) and on the website of BRLM i.e. Vivro Financial Services Private Limited at [www.vivro.net](http://www.vivro.net). Our Company invites the public to give their comments on the DRHP filed with the NSE, with respect to the disclosures made in the DRHP. The members of the public are requested to send the copies of their comments to NSE EMERGE and/or Company Secretary and the Compliance Officer of the Issuer and/or BRLM at their respective address mentioned below and the same should reach on or before 5:00 P.M. on the 21st day from the aforesaid date of filing of DRHP with NSE EMERGE.

Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the issuer and the Issuer including the risks involved. The securities have not been recommended or approved by the Securities and Exchange Board of India ("SEBI") nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited to the section titled "Risk factors" on page 31 of the Draft Red Herring Prospectus.

Any investment decision may only be taken after the red herring prospectus ("Red Herring Prospectus" or "RHP") has been filed with RoC and must be based solely on the basis of such RHP, as there may be any material changes in the RHP from the DRHP. Equity Shares, when offered through RHP are proposed to be listed on NSE EMERGE.

For details of share capital and capital structure of the Company and the names of the signatories to the Memorandum of the Association and number of Equity Shares subscribed by them, see "Capital Structure" on page 87 of the DRHP. The Liability of the members of our company is limited.

For details of the main objects of the issue as contained in the Memorandum of the Association, see "History and Certain Corporate Matters" on page 200 of the DRHP.

#### BOOK RUNNING LEAD MANAGER TO THE ISSUE

## VIVRO

Vivro Financial Services Private Limited  
 Vivro House, 11 Shashi Colony,  
 Opp. Suvdha Shopping Center,  
 Paldi, Ahmedabad - 380007  
 Gujarat, India.  
 Telephone: +91-79-4040 4242  
 E-mail Id: [investors@vivro.net](mailto:investors@vivro.net)  
 Investor Grievance Id: [investor\\_grievance@vivro.net](mailto:investor_grievance@vivro.net)  
 Website: [www.vivro.net](http://www.vivro.net)  
 Contact Person: Kruti Saraiya/Jay Dodiya  
 SEBI Registration No.: INMR000010122  
 CIN: U67120GJ1996PTC029182

#### REGISTRAR TO THE ISSUE

## MUFG

MUFG Intime India Private Limited  
 (Formerly known as  
 Link Intime India Private Limited)  
 C-101, 247 Park, L B S Marg, Vikhroli (West),  
 Mumbai 400083, (Maharashtra), India.  
 Telephone: +91 810 811 4949  
 Website: [www.mpmis.mufg.com](http://www.mpmis.mufg.com)  
 Email Id: [compliance@mpmis.mufg.com](mailto:compliance@mpmis.mufg.com)  
 Investor Grievance: [neochem.smeipo@mpmis.mufg.com](mailto:neochem.smeipo@mpmis.mufg.com)  
 Contact Person: Shanti Gopal Krishnan  
 SEBI Registration No.: INR000004058  
 CIN: U67190MH1999PTC118368

#### COMPANY SECRETARY AND COMPLIANCE OFFICER

## NEOCHEM

Neochem Bio Solutions Limited  
 Shraddha Sarthak Agarwal  
 Company Secretary and Compliance Officer  
 303, W1, Opp. Vikramnagar Colony, Off. Iscon - Ambli Road,  
 Ambli, Ahmedabad - 380058, Daskroi, Gujarat, India.  
 Telephone: +91-079-35217792  
 Email Id: [compliance@neochem.in](mailto:compliance@neochem.in)  
 Website: [www.neochem.in](http://www.neochem.in)

All the capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in DRHP.

For, Neochem Bio Solutions Limited

Shraddha Sarthak Agarwal  
 Company Secretary & Compliance Officer

Date : August 4, 2025

Place : Ahmedabad

Neochem Bio Solutions Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and considerations, to make initial public issue of Equity Shares and has filed DRHP with NSE EMERGE on August 4, 2025. The DRHP is available on the website of NSE at [www.nseindia.com](http://www.nseindia.com), Issuer at [www.neochem.in](http://www.neochem.in) and on the website of BRLM i.e. Vivro Financial Services Private Limited at [www.vivro.net](http://www.vivro.net). Any potential investor should note that the investment in the Equity Shares involves high degree of risk and for details relating to such risk kindly refer "Risk Factors" on page 31 of the DRHP. Potential investors should not rely on the DRHP filed with NSE EMERGE for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering of the Equity Shares in the United States.

KIRIN ADVISORS



## MERCANTILE VENTURES LIMITED

CIN: L65191TN1985PLC037309  
 Regd. Office: 88, Mount Road, Guindy, Chennai - 600 032 Tel: 044-4042209  
 Email: [admin@mercantileventures.co.in](mailto:admin@mercantileventures.co.in) website: [www.mercantileventures.co.in](http://www.mercantileventures.co.in)

#### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of Mercantile Ventures Limited ("Company") at its meeting held on Monday, 04<sup>th</sup> August 2025 approved the Unaudited Standalone and Consolidated financial results for the quarter ended 30<sup>th</sup> June 2025 ("results").

The results, along with the limited review report (standalone and consolidated) by M/s. Venkatesh & Co, Statutory Auditor of the Company are available on the website of the Company at <https://www.mercantileventures.co.in>, and on website of the Stock Exchange i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com).

In compliance with Regulation 47 of the SEBI Listing Regulations, we hereby notify that the same can be accessed by scanning the following Quick Response (QR) code:



For Mercantile Ventures Limited

E N Rangaswami  
 Whole-time Director  
 DIN: 06463753